GlobeNewswire: Rubius Therapeutics Contains the last 10 of 124 releaseshttp://www.globenewswire.com/External?Length=42024-03-30T06:43:10ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2022/11/02/2546990/0/en/Rubius-Therapeutics-Announces-Process-to-Explore-Strategic-Alternatives-and-Leadership-Changes.html?f=22&fvtc=4&fvtv=49324Rubius Therapeutics Announces Process to Explore Strategic Alternatives and Leadership Changes2022-11-02T20:01:00Z<![CDATA[Dannielle Appelhans to Become President and Chief Executive Officer]]>https://www.globenewswire.com/news-release/2022/09/19/2518259/0/en/Rubius-Therapeutics-to-Present-at-Guggenheim-Nantucket-Therapeutics-Conference.html?f=22&fvtc=4&fvtv=49324Rubius Therapeutics to Present at Guggenheim Nantucket Therapeutics Conference2022-09-19T12:00:00Z<![CDATA[CAMBRIDGE, Mass., Sept. 19, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a biopharmaceutical company that is developing an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatment of cancer and autoimmune diseases, today announced that Pablo J. Cagnoni, M.D., president and chief executive officer, will participate in a fireside chat at the Guggenheim Nantucket Therapeutics Conference on Thursday, September 29, 2022, at 11:15am EDT.]]>https://www.globenewswire.com/news-release/2022/09/13/2514844/0/en/Rubius-Therapeutics-Announces-Strategic-Update.html?f=22&fvtc=4&fvtv=49324Rubius Therapeutics Announces Strategic Update2022-09-13T11:00:00Z<![CDATA[Company to Focus on Advancing Next Generation Red Blood Cell-Based Cell Conjugation Platform]]>https://www.globenewswire.com/news-release/2022/09/12/2514501/0/en/Rubius-Therapeutics-to-Provide-Strategic-Update.html?f=22&fvtc=4&fvtv=49324Rubius Therapeutics to Provide Strategic Update2022-09-12T20:30:00Z<![CDATA[Investor Teleconference and Webcast Scheduled Tomorrow, September 13, 2022, at 7:30 a.m. EDT Investor Teleconference and Webcast Scheduled Tomorrow, September 13, 2022, at 7:30 a.m. EDT]]>https://www.globenewswire.com/news-release/2022/08/09/2494812/0/en/Rubius-Therapeutics-Reports-Second-Quarter-2022-Financial-Results-and-Provides-Business-Update.html?f=22&fvtc=4&fvtv=49324Rubius Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update2022-08-09T12:00:00Z<![CDATA[New Preclinical Data Presented at the FOCIS 2022 Annual Meeting Demonstrating Prevention of Type 1 Diabetes in a Stringent Preclinical Model]]>https://www.globenewswire.com/news-release/2022/07/26/2485851/0/en/Rubius-Therapeutics-to-Announce-Second-Quarter-2022-Financial-Results.html?f=22&fvtc=4&fvtv=49324Rubius Therapeutics to Announce Second Quarter 2022 Financial Results2022-07-26T12:00:00Z<![CDATA[CAMBRIDGE, Mass., July 26, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is biologically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatment of cancer and autoimmune diseases, today announced plans to report second quarter financial results on Tuesday, August 9, 2022, before market open.]]>https://www.globenewswire.com/news-release/2022/07/14/2479680/0/en/Rubius-Therapeutics-Appoints-Susanne-Schaffert-Ph-D-to-its-Board-of-Directors.html?f=22&fvtc=4&fvtv=49324Rubius Therapeutics Appoints Susanne Schaffert, Ph.D., to its Board of Directors2022-07-14T12:00:00Z<![CDATA[CAMBRIDGE, Mass., July 14, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is biologically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatment of cancer and autoimmune diseases, today announced the appointment of Susanne Schaffert, Ph.D., to its board of directors. Dr. Schaffert brings more than 25 years of experience across clinical development, marketing and sales, finance and commercialization in the global pharmaceutical and biotechnology industries, with a focus on oncology, immuno-oncology and cell therapy. Dr. Schaffert most recently served as President of Novartis Oncology. Also, today, Rubius announced that Anne Prener, M.D., Ph.D., is stepping down from her role on the board of directors, effective today.]]>https://www.globenewswire.com/news-release/2022/06/22/2467045/0/en/Rubius-Therapeutics-Presents-Updated-Data-from-its-Type-1-Diabetes-Preclinical-Program-at-the-Federation-of-Clinical-Immunology-Societies-FOCIS-2022-Annual-Meeting.html?f=22&fvtc=4&fvtv=49324Rubius Therapeutics Presents Updated Data from its Type 1 Diabetes Preclinical Program at the Federation of Clinical Immunology Societies (FOCIS) 2022 Annual Meeting2022-06-22T12:00:00Z<![CDATA[Prevention of Type 1 Diabetes in a Stringent Preclinical Model from Ongoing Experiment;Two Antigens Prevent Disease Driven by Many Autoantigens Demonstrating Bystander Suppression]]>https://www.globenewswire.com/news-release/2022/06/01/2454177/0/en/Rubius-Therapeutics-to-Present-at-the-Jefferies-Global-Healthcare-Conference.html?f=22&fvtc=4&fvtv=49324Rubius Therapeutics to Present at the Jefferies Global Healthcare Conference2022-06-01T12:00:00Z<![CDATA[CAMBRIDGE, Mass., June 01, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is biologically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatment of cancer and autoimmune diseases, today announced that Pablo J. Cagnoni, M.D., president and chief executive officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 9, 2022, at 2:30 p.m. EDT.]]>https://www.globenewswire.com/news-release/2022/05/26/2451647/0/en/Rubius-Therapeutics-to-Present-Trials-in-Progress-Poster-for-the-Phase-1-2-Clinical-Trial-of-RTX-224-in-Select-Advanced-Solid-Tumors-at-the-2022-American-Society-of-Clinical-Oncolo.html?f=22&fvtc=4&fvtv=49324Rubius Therapeutics to Present Trials in Progress Poster for the Phase 1/2 Clinical Trial of RTX-224 in Select Advanced Solid Tumors at the 2022 American Society of Clinical Oncology Annual Meeting2022-05-26T21:00:00Z<![CDATA[CAMBRIDGE, Mass., May 26, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatment of cancer and autoimmune diseases, today announced that the Company will present a Trials in Progress poster presentation for its second broad immune stimulation program, RTX-224, at the American Society of Clinical Oncology (ASCO) Annual Meeting being held virtually from June 3-7, 2022.]]>